Gupta A. et al., 2021: Evaluation of immediate and short-term efficacy of DualStim therapy with and without intracavernosal umbilical cord-derived Wharton's jelly in patients with erectile dysfunction: Study protocol for a randomized controlled trial.
Gupta A, Rodriguez HC, Delfino K, Levy HJ, El-Amin SF 3rd, Gaines R.
BioIntegrate, Lawrenceville, GA, USA.
Future Biologics, Lawrenceville, GA, USA.
South Texas Orthopaedic Research Institute, Laredo, TX, USA.
Veterans in Pain, Los Angeles, CA, USA.
University of the Incarnate Word, School of Osteopathic Medicine, San Antonio, TX, USA.
Future Physicians of South Texas, San Antonio, TX, USA.
Southern Illinois University, School of Medicine, Springfield, IL, USA.
Department of Orthopaedic Surgery, Lenox Hill Hospital, Northwell Health, New York, NY, USA.
El-Amin Orthopaedic and Sports Medicine Institute, Lawrenceville, GA, USA.
LifeGaines Medical and Aesthetics, Boca Raton, FL, USA.
Introduction: Erectile dysfunction (ED) affects a significant portion of the United States population and causes negative psychological burdens that affects men and their partner's quality of life and satisfaction. Extracorporeal shock therapy (ESWT) utilizing focused ESWT and radial ESWT in Low-intensity shock wave therapy has been used to treat ED with some success. Wharton's Jelly (WJ) is a biologic substance with large amounts of stem cells, growth factors, cytokines and extracellular components. The use of combined focused and radial ESWT (DualStim therapy) with injected WJ have potential uses in ED that may have advantages over current treatments.
Materials: A randomized, single-blinded, controlled clinical trial will be conducted to evaluate the efficacy and safety of DualStim therapy and intracavernosal injection of WJ in moderate to severe ED. A total of 60 patients with moderate to severe ED will be enrolled and treated with DualStim therapy with intracavernosal injection of WJ or saline for a period of 7 weeks. The International Index of Erectile Function - Erectile Function score will be used to gauge the treatment related changes in relation to the subject's baseline. The scores will be recorded at baseline and compared to follow-ups 1,3 and 6 months post-treatment. Any adverse events or severe adverse events will be recorded in the corresponding case report forms. Sexual Encounter Profile, as well as the Global Assessment Questionnaire and the Erection Hardness Score will be used to determine the sexual activity improvement from baseline leading to optimal penetration at follow-ups 1,3 and 6 months post-treatment.
Discussion: This clinical trial is one of the first studies to determine the immediate and short-term efficacy of DualStim therapy, with and without intracavernosal injection of formulated umbilical cord-derived WJ to improve and/or restore erectile function in patients with moderate to severe ED. This study will also provide insight into the safety and efficacy of WJ. We anticipate clinically significant improvement in patients suffering from moderate and severe ED treated with DualStim therapy with WJ compared to their baseline and DualStim with saline.
Contemp Clin Trials Commun. 2021 May 29;23:100790. doi: 10.1016/j.conctc.2021.100790. eCollection 2021 Sep. PMID: 34278040. FREE ARTICLE